Thai National Guideline for Nuclear Medicine Investigation in Movement Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration

Overview

Journal Asia Ocean J Nucl Med Biol

Specialty Nuclear Medicine

Date 2024 Jul 25

PMID 39050239

Authors

Tawika Kaewchur

Benjapa Khiewvan

Wichana Chamroonrat

Praween Lolekha

Onanong Phokaewvarangkul

Tanyaluck Thientunyakit

Nantaporn Wongsurawat

Peerapon Kiatkittikul

Chanisa Chotipanich

Wen-Sheng Huang

Panya Pasawang

Tanawat Sontrapornpol

Nucharee Poon-Iad

Sasithorn Amnuaywattakorn

Supatporn Tepmongkol

Affiliations

Soon will be listed here.

Abstract

Movement disorders are chronic neurological syndromes with both treatable and non-treatable causes. The top causes of movement disorders are Parkinson's disease and related disorders. Functional imaging investigations with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) images play vital roles in diagnosis and differential diagnosis to guide disease management. Since there have been new advanced imaging technologies and radiopharmaceuticals development, there is a need for up-to-date consensus guidelines. Thus, the Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and the Thai Medical Physicist Society collaborated to establish the guideline for Nuclear Medicine investigations in movement disorder for practical use in patient care. We have extensively reviewed the current practice guidelines from other related societies and good quality papers as well as our own experience in Nuclear Medicine practice in movement disorders. We also adjust for the most suitability for application in Thailand and other developing countries.

Citing Articles

Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration.

Kaewchur T, Thientunyakit T, Chamroonrat W, Khiewvan B, Kiatkittikul P, Wongsurawat N Diagnostics (Basel). 2024; 14(22).

PMID: 39594140 PMC: 11592784. DOI: 10.3390/diagnostics14222474.

References

Montastruc J, Llau M, Rascol O, Senard J . Drug-induced parkinsonism: a review. Fundam Clin Pharmacol. 1994; 8(4):293-306. DOI: 10.1111/j.1472-8206.1994.tb00808.x. View

Schwingenschuh P, Ruge D, Edwards M, Terranova C, Katschnig P, Carrillo F . Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010; 25(5):560-9. PMC: 2996567. DOI: 10.1002/mds.23019. View

Brajkovic L, Kostic V, Sobic-Saranovic D, Stefanova E, Jecmenica-Lukic M, Jesic A . The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurol Res. 2017; 39(8):675-684. DOI: 10.1080/01616412.2017.1312211. View

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon E, Schlossmacher M . Canadian guideline for Parkinson disease. CMAJ. 2019; 191(36):E989-E1004. PMC: 6733687. DOI: 10.1503/cmaj.181504. View

Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N . SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging. 2010; 38(4):764-73. DOI: 10.1007/s00259-010-1664-1. View

Goetz C, Emre M, Dubois B . Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2009; 64 Suppl 2:S81-92. DOI: 10.1002/ana.21455. View

Song I, Ha S, Yang Y, Chung Y . Differences in Regional Glucose Metabolism of the Brain Measured with F-18-FDG-PET in Patients with Essential Tremor According to Their Response to Beta-Blockers. Korean J Radiol. 2015; 16(5):967-72. PMC: 4559793. DOI: 10.3348/kjr.2015.16.5.967. View

Rajput A, ROZDILSKY B, Rajput A . Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci. 1991; 18(3):275-8. DOI: 10.1017/s0317167100031814. View

Eckert T, Barnes A, Dhawan V, Frucht S, Gordon M, Feigin A . FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005; 26(3):912-21. DOI: 10.1016/j.neuroimage.2005.03.012. View

10.

Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma R . Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019; 34(10):1464-1470. DOI: 10.1002/mds.27802. View

11.

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

12.

Booij J, Kemp P . Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2007; 35(2):424-38. DOI: 10.1007/s00259-007-0621-0. View

13.

Arbizu J, Luquin M, Abella J, de la Fuente-Fernandez R, Fernandez-Torron R, Garcia-Solis D . [Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use]. Rev Esp Med Nucl Imagen Mol. 2014; 33(4):215-26. DOI: 10.1016/j.remn.2014.02.001. View

14.

Linke R, Gostomzyk J, Hahn K, Tatsch K . [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med. 2001; 27(12):1809-12. DOI: 10.1007/s002590000384. View

15.

Brooks D, Salmon E, Mathias C, Quinn N, Leenders K, Bannister R . The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990; 113 ( Pt 5):1539-52. DOI: 10.1093/brain/113.5.1539. View

16.

Yoshita M . Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998; 155(1):60-7. DOI: 10.1016/s0022-510x(97)00278-5. View

17.

Hellwig S, Amtage F, Kreft A, Buchert R, Winz O, Vach W . [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012; 79(13):1314-22. DOI: 10.1212/WNL.0b013e31826c1b0a. View

18.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen A, van Royen E . Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998; 39(7):1143-8. View

19.

Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J . Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6. PMC: 2676993. DOI: 10.1212/01.wnl.0000324625.00404.15. View

20.

Meyer P, Frings L, Rucker G, Hellwig S . F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017; 58(12):1888-1898. DOI: 10.2967/jnumed.116.186403. View